Clinical trial · Interventional
Compassionate Treatment in Children With Brain Tumors With the Cytotron®
Study in Children With Brain Tumors in Terminal Stages Using Advanced Functional Magnetic Resonance Imaging in a Compassionate Palliative Care Setting, With Quantum Magnetic Resonance Therapy (QMRT).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): suspended due to administrative problems
Summary
Brief summary (as posted)
This is a prospective case-control study. This study is expected to last for approximately 12 months, comprised of 4-8 weeks of enrollment period, 28 days of treatment and 6 months of follow up. The enrollment will be completed prior to the beginning of initial treatment. The study will be closed when 10 subjects have completed the study. The recruitment will be carried out with a sample at convenience.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Brain Tumor | Childhood Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| QMRT with the Cytotron® | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- QMRT using the Cytotron®
- description
- Experimental: QMRT using the Cytotron® Intervention: 28 days of treatment with QMRT with the Cytotron®. Patients diagnosed with terminal brain tumors between 3 and 16 years of age whose parents agree to participate in the study and have signed informed consent and informed consent in patients with age or mental age over 8 years.
- interventionNames
- Procedure: QMRT with the Cytotron®
Primary outcomes (1)
- measure
- Quality of life with the Pediatric Quality of Life Inventory (PedsQL) brain tumors
- timeFrame
- 6 months
- description
- Change in the total score in the PedsQL of the patients diagnosed with brain tumor will be measured before starting the treatment and 6 months later. Higher values are going to represent a better outcome.
Secondary outcomes (5)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * A child 3 to 16 years of age. * A clinical diagnosis of terminal primary brain tumor * A diagnosis of a terminal brain tumor, which indicates that the patient is out of conventional treatment and does not have another therapeutic option. Exclusion Criteria: * Patients with metastasis * Patients requiring oxygen or mechanical ventilation * Current or recent history (within 2 months) of significant bacterial, fungal, viral, or mycobacterial infection. * Having a condition considered as causing or likely to cause co-morbidities, as determined by the investigator based on medical history, physical examination, vital signs, and clinical laboratory tests. * Subject with magnetic implants, pacemakers, claustrophobia or any other condition that precludes them from entering or staying in the treatment device. * Children with previous neurosurgery within 6 months at the time of screening. * History of myocardial infarction, congestive heart failure, or stroke. * Subject is exposed to secondary smoking in his/her home environment. * Subjects who are unable or unlikely to comply with the protocol, determined by the majority vote of the investigators.
References
Publications (1)
- DERIVEDBarragan-Perez EJ, Alvarez-Amado DE, Dies-Suarez P, Tobon SH, Garcia-Beristain JC, Penaloza-Gonzalez JG. Compassionate use of Quantum Magnetic Resonance Therapy for treatment of children with Diffuse Brainstem Glioma in Mexico City: a single institutional experience. J Neurooncol. 2022 Apr;157(2):377-382. doi: 10.1007/s11060-022-03972-2. Epub 2022 Mar 10. PMID 35266065